GLP-1 Receptor Expression Within the Human Heart
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Glucagonlike peptide-1 receptor (GLP-1R) agonists, which are used to treat type 2 diabetes and obesity, reduce the rates of myocardial infarction and cardiovascular death. GLP-1R has been localized to the human sinoatrial node; however, its expression in ventricular tissue remains uncertain. Here we studied GLP-1R expression in the human heart using GLP-1R-directed antisera, quantitative polymerase chain reaction (PCR), reverse transcription PCR to detect full-length messenger RNA (mRNA) transcripts, and in situ hybridization (ISH). GLP1R mRNA transcripts, encompassing the entire open reading frame, were detected in all four cardiac chambers from 15 hearts at levels approximating those detected in human pancreas. In contrast, cardiac GLP2R expression was relatively lower, and cardiac GCGR expression was sporadic and not detected in the left ventricle. GLP1R mRNA transcripts were not detected in RNA from human cardiac fibroblasts, coronary artery endothelial, or vascular smooth muscle cells. Human Brunner glands and pancreatic islets exhibited GLP-1R immunopositivity and abundant expression of GLP1R mRNA transcripts by ISH. GLP1R transcripts were also detected by ISH in human cardiac sinoatrial node tissue. However, definitive cellular localization of GLP1R mRNA transcripts or immunoreactive GLP-1R protein within human cardiomyocytes or cardiac blood vessels remained elusive. Moreover, validated GLP-1R antisera lacked sufficient sensitivity to detect expression of the endogenous islet or cardiac GLP-1R by Western blotting. Hence, although human cardiac ventricles express the GLP1R, the identity of one or more ventricular cell type(s) that express a translated GLP1R protein requires further clarification with highly sensitive methods of detection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [40]
In the citing paper
“However, while Glp1r is not expressed appreciably in mouse cardiomyocytes, some human ventricular and atrial cardiomyocytes do express GLP1R (40, 57).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [40]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 8×
“First Published Online 12 February 2018 Abbreviations: BHK, baby hamster kidney; CFPAC-1, cystic fibrosis pancreatic adenocarcinoma; GLP-1, glucagonlike peptide-1; GLP-1R, glucagonlike peptide-1 receptor; ISH, in situ hybridization; PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; RT-PCR,…”
BackgroundInfluentialSelf-citationFagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“(GLP-1), are secreted from the gut after meal ingestion and amplify glucose-dependent insulin secretion (1).”
BackgroundSelf-citationLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“significantly alter the rate of major adverse cardiovascular events (18).”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 8×
“First Published Online 12 February 2018 Abbreviations: BHK, baby hamster kidney; CFPAC-1, cystic fibrosis pancreatic adenocarcinoma; GLP-1, glucagonlike peptide-1; GLP-1R, glucagonlike peptide-1 receptor; ISH, in situ hybridization; PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; RT-PCR,…”
BackgroundInfluentialSelf-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 5×
“with the previous detection of GLP-1Rswithin human and nonhuman primate atrial tissue (23), implicates one or more direct roles forGLP-1R signaling in the human heart.”
BackgroundMethodInfluentialNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Self-citationThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Self-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“Activation of GLP-1R signaling rapidly improves ventricular function in the context of transient ischemia in preclinical and clinical studies (14) and reduces infarct size in experimentalmodels of ischemia secondary to coronary artery ligation (15, 16).”
BackgroundSelf-citationExenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., Jørgensen, E., Helqvist, S., Saunamäki, K., Clemmensen, P., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr309 · Cited by 550
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
Self-citationDavies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372 · cited 1×
“1 (Thermo Fisher) were generated as described (29).”
MethodSelf-citationCardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Self-citationCampos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Self-citationPanjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 1×
“Moreover, detection of the immunoreactive GLP-1R has proven challenging due to the suboptimal sensitivity and specificity of the available reagents (24, 25).”
BackgroundSelf-citationThe Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
Self-citationIncretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272 · cited 1×
“antibody 3F52 (23) and the polyclonal antibody Novus 19400002 (31).”
BackgroundSelf-citationEmerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Self-citationThe Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154
Jensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N.-H., Deacon, C. F., Jensen, B. L., Holst, J. J., & Sorensen, C. M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2014 · Cited by 141 · cited 1×
“GLP-1R has been reported in studies of human coronary artery endothelial cells and in rat kidney vascular smooth muscle cells (40, 41).”
ResultRead, P. A., Hoole, S. P., White, P. A., Khan, F. Z., O'Sullivan, M., West, N. E. J., & Dutka, D. P. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.110.960476 · Cited by 119
Read, P. A., Khan, F. Z., & Dutka, D. P. (2012) · Heart · doi:10.1136/hrt.2010.219345 · Cited by 113
Ussher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 108
Self-citationKaur, H., Carvalho, J., Looso, M., Singh, P., Chennupati, R., Preussner, J., Günther, S., Albarrán-Juárez, J., Tischner, D., Classen, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15700 · Cited by 97
Subaran, S. C., Sauder, M. A., Chai, W., Jahn, L. A., Fowler, D. E., Aylor, K. W., Basu, A., & Liu, Z. (2014) · Clinical Science · doi:10.1042/cs20130708 · Cited by 95
Gejl, M., Søndergaard, H. M., Stecher, C., Bibby, B. M., Møller, N., Bøtker, H. E., Hansen, S. B., Gjedde, A., Rungby, J., & Brock, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3456 · Cited by 78
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
Wohlfart, P., Linz, W., Hübschle, T., Linz, D., Huber, J., Hess, S., Crowther, D., Werner, U., & Ruetten, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-84 · Cited by 78
Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojević-Holzer, S., Thon-Gutschi, E., Sourij, H., Kapl, M., Edmunds, N. J., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.09.018 · Cited by 75
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets
Zhou, J., Livak, M. F. A., Bernier, M., Muller, D. C., Carlson, O. D., Elahi, D., Maudsley, S., & Egan, J. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00070.2007 · Cited by 73
Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69
Self-citationVascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
Self-citationKoehler, J. A., & Drucker, D. J. (2006) · Diabetes · doi:10.2337/db05-1145 · Cited by 60
Self-citationFunctional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 43
The endogenous preproglucagon system is not essential for gut growth homeostasis in mice
Wismann, P., Barkholt, P., Secher, T., Vrang, N., Hansen, H. B., Jeppesen, P. B., Baggio, L. L., Koehler, J. A., Drucker, D. J., Sandoval, D. A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.007 · Cited by 43
Self-citationLiu, Y., Huang, Z., Wang, L., Liu, X., Wang, Y.-M., Zhang, Y., & Zhang, M. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.12.007 · Cited by 38
Qa’aty, N., Wang, Y., Wang, A., Mao, S., Vincent, M. L., Husain, M., & Hinek, A. (2014) · Endocrinology · doi:10.1210/en.2014-1519 · Cited by 27
Nakamura, Y., Kanai∥, T., Saeki, K., Takabe, M., Irie, J., Miyoshi, J., Mikami, Y., Teratani, T., Suzuki, T., Miyata, N., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00318.2012 · Cited by 13
Artinian, S. B., Lafi, S. M. A., Boutary, S. S., Bitar, K. M., Zwainy, N. S., & Bikhazi, A. B. (2011) · Experimental Diabetes Research · doi:10.1155/2011/489708 · Cited by 8
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Surprisingly, in one recent study, robust expression of the GLP-1 receptor mRNA was also reported in human cardiac ventricles, but the exact localization of the GLP-1R protein could not be determined [613].”
BackgroundSelf-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Epicardial adipose tissue in contemporary cardiology
Iacobellis, G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00679-9 · Cited by 797
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Self-citation
Metadata
- Authors
- Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- University Health Network (CA)
- Hospital of the University of Pennsylvania (US)
- Corresponding author
- Drucker, Daniel J
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2018-02-12
- Volume
- 159
- Issue
- 4
- Pages
- 1570-1584
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC5939638
- OpenAlex
- W2790252631
- Cited by
- 312
- References
- 48
- Citations by year
- 2026: 51 · 2025: 47 · 2024: 46 · 2023: 28 · 2022: 40 · 2021: 27 · 2020: 22 · 2019: 36 · 2018: 15
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (154321)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, human heart, cardiac ventricle, sinoatrial node, GLP-2 receptor, glucagon receptor, cardiomyocytes, Brunner glands, pancreatic islets, GLP-1 receptor agonists
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Animals, Cell Line, Female, Fibroblasts, Cricetinae, Humans, Islets of Langerhans, Muscle, Smooth, Vascular, Myocardium, Myocytes, Smooth Muscle
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.